Boston Pharmaceuticals (United States)

Alternate names: Boston Pharmaceuticals, Boston Pharmaceuticals Inc.

ROR: 00fk46e73

OpenAlex ID: I4405270318

TET2 -Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial

2022 · Eric C. Svensson, Aviv Madar, et al. · JAMA Cardiology · 420

PDF

Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity

2022 · Rachid Essalmani, Jaspreet Jain, et al. · Journal of Virology · 199

PDF

First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer

2021 · Mark D. Pegram, Erika P. Hamilton, et al. · Molecular Cancer Therapeutics · 111

Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double‐blind, phase 2 trial

2021 · Susanne Tan, Stanislav Ignatenko, et al. · Diabetes Obesity and Metabolism · 59

PDF

Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial

2025 · Rohit Loomba, Kris V Kowdley, et al. · The Lancet. Gastroenterology & hepatology · 52

BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET -altered tumors including RET -fusion+ NSCLC and RET -mutant MTC: Phase 1 study results.

2021 · Patrick Schoffski, Byoung Chul Cho, et al. · Journal of Clinical Oncology · 45

Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer

2022 · Laura M. Spring, Hyo Han, et al. · Nature Cancer · 33

PDF

A highly selective, cell-permeable furin inhibitor BOS-318 rescues key features of cystic fibrosis airway disease

2022 · Lisa E.J. Douglas, James A. Reihill, et al. · Cell chemical biology · 33

PDF

2020 White Paper on Recent Issues in Bioanalysis: BAV Guidance, CLSI H62, Biotherapeutics Stability, Parallelism Testing, CyTOF and Regulatory Feedback ( Part 2A –Recommendations on Biotherapeutics Stability, PK LBA Regulated Bioanalysis, Biomarkers Assays, Cytometry Validation & Innovation Part 2B –Regulatory Agencies’ Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine)

2021 · Susan Spitz, Yan Zhang, et al. · Bioanalysis · 33

PDF

A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer.

2019 · Patrick Schoffski, Philippe Georges Aftimos, et al. · Journal of Clinical Oncology · 33

Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children

2020 · Andrew DJ. Pearson, Kimberly Stegmaier, et al. · European Journal of Cancer · 26

PDF

Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial

2026 · Mazen Noureddin, Kris V Kowdley, et al. · The Lancet · 20

A Genomic Link From Heart Failure to Atrial Fibrillation Risk: FOG2 Modulates a TBX5/GATA4-Dependent Atrial Gene Regulatory Network

2024 · Michael T. Broman, Rangarajan D. Nadadur, et al. · Circulation · 20

PDF

Erratum for Essalmani et al., “Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity”

2022 · Rachid Essalmani, Jaspreet Jain, et al. · Journal of Virology · 20

Best practices for the development and fit-for-purpose validation of biomarker methods: a conference report

2022 · Joel Mathews, Lakshmi Amaravadi, et al. · AAPS Open · 20

PDF

A Double‐Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects

2019 · Azra Hussaini, Rajat Mukherjee, et al. · Clinical and Translational Science · 20

PDF

Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia

2017 · Xiaofei Zhou, Diane R. Mould, et al. · British Journal of Clinical Pharmacology · 19

PDF

Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range

2017 · Michael J. Hanley, Diane R. Mould, et al. · The Journal of Clinical Pharmacology · 17

PDF

SARS-CoV-2 spike-glycoprotein processing at S1/S2 and S2’and shedding of the ACE2 viral receptor: roles of Furin and TMPRSS2 and implications for viral infectivity and cell-to-cell fusion

2020 · Rachid Essalmani, Jaspreet Jain, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 11

PDF

Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis

2020 · Pavel Kovalenko, Anne Paccaly, et al. · CPT Pharmacometrics & Systems Pharmacology · 11

PDF

Abstract 2199: BOS172738: A novel highly potent and selective RET kinase inhibitor in Phase 1 clinical development

2019 · Mitchell Keegan, Keith Wilcoxen, et al. · Cancer Research · 10

Metabolism and Excretion of [14C]Mobocertinib, a Selective Covalent Inhibitor of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations, in Healthy Male Subjects

2024 · Hao Chen, Abhi Shah, et al. · Drug Metabolism and Disposition · 8

Clinical assessment of gepotidacin ( GSK2140944 ) as a victim and perpetrator of drug–drug interactions via CYP3A metabolism and transporters

2023 · Aline Barth, Caroline R. Perry, et al. · Clinical and Translational Science · 8

Is Incurred Sample Reanalysis (ISR) Applicable in Biomarker Assays?

2022 · Amanda Hays, Lakshmi Amaravadi, et al. · The AAPS Journal · 8

BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study

2025 · P. Schöffski, A. Gazzah, et al. · ESMO Open · 4

Works count: 41

Citation count: 2,641